Reported Saturday, Johnson & Johnson's TREMFYA Maintains 80% Clinical Remission And 53% Endoscopic Remission In Ulcerative Colitis Through Week 140 Of Long-Term QUASAR Extension Study
Johnson & Johnson -0.23%
Johnson & Johnson JNJ | 239.55 | -0.23% |
Reported Saturday, Johnson & Johnson's TREMFYA Maintains 80% Clinical Remission And 53% Endoscopic Remission In Ulcerative Colitis Through Week 140 Of Long-Term QUASAR Extension Study
